首页|二陈汤加减联合多烯磷脂酰胆碱胶囊治疗代谢相关脂肪性肝病临床观察

二陈汤加减联合多烯磷脂酰胆碱胶囊治疗代谢相关脂肪性肝病临床观察

扫码查看
目的 观察二陈汤加减联合多烯磷脂酰胆碱胶囊治疗代谢相关脂肪性肝病(MAFLD)的临床疗效.方法 将196 例MAFLD患者按照随机数字表法分为2 组,均对患者饮食方式、生活方式等进行常规指导,治疗组 98 例予二陈汤加减联合多烯磷脂酰胆碱胶囊治疗,对照组98 例予多烯磷脂酰胆碱胶囊治疗,2 组均治疗12 周.比较2 组疗效;比较2 组治疗前后体质量指数(BMI)、腰围、肝功能指标、血脂指标、B超评分、症状评分变化.结果 治疗组总有效率90.82%(89/98),对照组总有效率76.53%(75/98),治疗组疗效优于对照组(P<0.05).治疗组治疗第 4、8、12 周BMI均较本组治疗前降低(P<0.05),治疗组治疗第8、12 周BMI均较本组治疗第 4 周降低(P<0.05).对照组治疗前及治疗第4、8、12 周BMI比较差异均无统计学意义(P>0.05).治疗组治疗第4、8、12 周BMI改善均优于对照组(P<0.05).2 组治疗后腰围均较本组治疗前降低(P<0.05).2 组治疗第4、8、12 周ALT、AST、γ-GT水平均较本组治疗前降低(P<0.05);治疗组治疗第4、8、12 周ALT水平均低于对照组治疗同期(P<0.05);治疗组治疗第8、12 周AST水平均低于对照组治疗同期(P<0.05).2 组治疗第4、8、12 周TC、TG水平均较本组治疗前降低(P<0.05),治疗第4、8、12 周HDL-C水平均较本组治疗前升高(P<0.05);治疗组治疗第4、8、12 周TC、TG水平均低于对照组治疗同期(P<0.05),治疗第8、12 周HDL-C水平均高于对照组治疗同期(P<0.05).2 组治疗后B超评分均较本组治疗前降低(P<0.05),且治疗组降低更明显(P<0.05).2 组治疗后各项症状评分均较本组治疗前降低(P<0.05),且治疗组降低更明显(P<0.05).结论 二陈汤加减联合多烯磷脂酰胆碱胶囊治疗MAFLD,能降低BMI,缩小腰围,改善患者肝功能、血脂水平,改善B超评分和症状.
Clinical efficacy of Erchen Decoction combined with polyene phosphatidylcholine capsules on metabolic-associated fatty liver disease
Objective To observe the clinical efficacy of Erchen Decoction combined with polyene phosphatidylcholine capsules on metabolic-associated fatty liver disease(MAFLD).Methods A total of 196 patients with MAFLD were divided into control group(n=98)and treatment group(n=98)according to a random number table.All patients were given routine guidance on diet and lifestylem,patients in the treatment group additonally received modified Erchen Decoction puls polyene phosphatidylcholine capsules.But those in the control group received the later only.A 12-week treatmeat was performed.The curative effects of the two groups were compared.The changes in body mass index(BMI)and waist circumference(WC),inde-xes of liver function and blood lipid,scores of B-ultrasound examination and traditional Chinese medicine(TCM)symptom be-fore and after treatment were included as comparators between the two groups.Results The total effective rate in the treatment group was significantly higher than that of the control group(90.81%[89/98]vs 76.53%[75/98],P<0.05).The levels of BMI in the treatment group at weeks 4,8 and 12 were signifi-cantly lower than those before treatment(P<0.05).The levels of BMI of the treatment group at weeks 8 and 12 were significantly lower than those at week 4(P<0.05).There was no significant difference in BMI level in the control group before and after treatment(P>0.05).The improvement of BMI in the treatment group was significantly better than that of the control group(P<0.05).The levels of WC in the two groups after treatment were significantly lower than those before treatment(P<0.05).The levels of alanine aminotransferase(ALT),aspartate aminotrans-ferase(AST),gamma-glutamyltransferase(γ-GT)in the two groups at weeks 4,8 and 12 were significantly lower than those before treatment(P<0.05).The levels of ALT at weeks 4,8 and12 in the treatment group were significantly lower than those of the control group(P<0.05).The levels of AST at weeks8 and12 in the treatment group were significantly lower than those of the control group(P<0.05).The levels of total cholesterol(TC)and triglycerides(TG)in the two groups at weeks 4,8 and 12 were lower than those before treatment(P<0.05),but the levels of high-density lipoprotein cholesterol(HDL-C)were higher(P<0.05).The levels of TC and TG at weeks 4,8 and 12 in the treatment group were lower than those of the control group(P<0.05),but the levels of HDL-C at weeks 8 and 12 in the treatment group were higher than those of the control group(P<0.05).After treatment,the scores of B-ultrasound examination and TCM symptom in the two groups were lower than those before treatment(P<0.05),and the decreases in the treatment group were more significant(P<0.05).Conclu-sion Erchen Decoction combined with polyene phosphatidylcholine capsule in the treatment of MAFLD can reduce BMI,reduce WC,improve liver function and blood lipid level,and improve score of B-ultrasound examination and TCM symptoms.

Liver disease,nonalcoholicIntegrative medicine therapy

孙天琪、卢秉久、郑佳连

展开 >

辽宁中医药大学,辽宁 沈阳 110847

辽宁中医药大学附属医院肝病科,辽宁 沈阳 110032

肝疾病,非酒精性 中西医结合疗法

辽宁省教育厅2019年度科学研究经费项目

L201903

2024

河北中医
河北省医学情报研究所,河北省中医药学会

河北中医

CSTPCD
影响因子:0.951
ISSN:1002-2619
年,卷(期):2024.46(6)